摘要
目的探讨贝伐单抗联合化疗对EGFR非突变型肺腺癌患者的治疗作用及血清肿瘤标志物的影响。方法选取2020年1月—2021年1月于本院的EGFR非突变型肺腺癌患者76例,随机分为两组。对照组应用化疗,研究组应用化疗+贝伐单抗。结果治疗后研究组VEGF(316.41±30.15)pg/ml、CY-FRA21-1(2.03±0.45)ng/ml、CEA(12.21±2.34)ng/ml、CA50水平(17.34±2.51)U/ml均比对照组低(461.70±35.68)pg/ml、(3.45±0.51)ng/ml、(17.24±2.31)ng/ml、(23.01±3.34)U/ml(P<0.05);研究组控制率(92.0%)优于对照组(78.9%)(P<0.05);研究组皮疹(10.5%)、腹泻(5.3%)、出血发生率(2.6%)比对照组低(23.7%)、(10.5%)、(5.1%)(P<0.05);研究组治疗后CD_(3)^(+)(50.79%±4.13%)、CD_(4)^(+)(34.24%±4.24%)、CD_(4)^(+)/CD8+(1.03±0.03)均比对照组高(47.01%±4.34%)、(30.01%±3.01%)、(0.72±0.09),CD8+(34.14%±2.13%)比对照组低(36.05%±1.44%)(P<0.05)。结论EGFR非突变型肺腺癌患者应用化疗+贝伐单抗治疗效果较好,可以有效改善患者机体中的肿瘤标志物水平,降低发生不良反应的概率,提高治疗效果,改善其免疫功能,有利于生活质量的提高。
Objective To investigate the therapeutic effect of bevacizumab combined with chemotherapy on patients with EGFR non-mutant lung adenocarcinoma and the effect of serum tumor markers.Methods 76 patients with EGFR non-mutant lung adenocarcinoma admitted to the hospital from January 2020 to January 2021 were randomly divided into two groups.The control group received chemotherapy,and the study group received chemotherapy+bevacizumab.Results After treatment,the levels of VEGF(316.41±30.15)pg/ml,Cy-FRA21-1(2.03±0.45)ng/ml,CEA(12.21±2.34)ng/ml and CA50(17.34±2.51)U/ml in the study group were lower than those in the control group(461.70±35.68)pg/ml,(3.45±0.51)ng/ml,(17.24±2.31)ng/ml and(23.01±3.34)U/ml(P<0.05).The control rate of the study group(92.0%)was better than that of the control group(78.9%)(P<0.05).The incidence of rash(10.5%),diarrhea(5.3%)and bleeding(2.6%)in the study group were lower than those in the control group(23.7%),(10.5%)and(5.1%)(P<0.05).After treatment,CD_(3)^(+)(50.79%±4.13%),CD_(4)^(+)(34.24%±4.24%),CD_(4)^(+)/CD_(8)^(+)(1.03±0.03)in the study group were higher than those in the control group(47.01%±4.34%),(30.01%±3.01%)and(0.72±0.09),and CD_(8)^(+)(34.14%±2.13%)were lower than those in the control group(36.05%±1.44%)(P<0.05).Conclusion The treatment effect of chemotherapy+bevacizumab in EGFR non-mutant lung adenocarcinoma patients is good,which can effectively improve the level of tumor markers in patients’body,reduce the probability of adverse reactions,improve the treatment effect,improve their immune function,and improve the quality of life.
作者
朱永东
ZHU Yongdong(Xuancheng People's Hospital,Xuancheng 242000,China)
出处
《中国全科医学》
CAS
北大核心
2021年第S02期157-159,共3页
Chinese General Practice
